The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.
This is a substudy of the ongoing randomized trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin (EudraCT number: 2013-002553-29). 20 consecutive patients are anticipated to participate regardless of assignment to either orchiectomy or triptorelin.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
31
Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
Androgen deprivation therapy by bilateral subcapsular orchiectomy
Herlev Hospital
Herlev, Denmark
Change in hepatic fat content
Change in hepatic fat content measured by Magnetic Resonance Spectroscopy
Time frame: At baseline (within 4 weeks of commencement of androgen deprivation therapy) and after 24 weeks
Change in visceral/subcutaneous fat mass
Changes in visceral and subcutaneous fat mass measured by Magnetic Resonance Imaging.
Time frame: At baseline (within 4 weeks of commencement of androgen deprivation therapy) and after 24 weeks
Correlation between Hepatic fat content and baseline androgen status
To investigate possible correlation between androgen status before commencing androgen deprivation therapy and hepatic fat content at baseline.
Time frame: Androgen status measured before commencement of androgen deprivation therapy (ADT), hepatic fat content measured at baseline (within 1 month of commencing androgen deprivation therapy)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.